Skip to Main Content

Paper Details

Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry.
Eur Heart J Cardiovasc Pharmacother
6
2022
CAD, DPI, MALE, PAD, Patients, XATOA, acute or severe limb ischaemia, aspirin, coronary artery disease, patient, patients, peripheral artery disease, rivaroxaban, women
Author NameAffiliation
Manesh R PatelDuke Clinical Research Institute, Duke University
Sonia S AnandChanchlani Research Centre and the Population Health Research Institute, McMaster University
Sonia S AnandMcMaster University
  • 1 - 3

Datasets

Release 1.2